Phase II trial shows drug combination promising in advanced melanoma

the ONA take:

Clinical trial shows simultaneous administration of ipilimumab and nivolumab produced better treatment response in patients with advanced melanoma who had received no prior treatment.

The phase II, double-blind trial enrolled 142 patients with advanced melanoma who had not received prior treatments. The patients were randomly assigned to receive ipilimumab plus nivolumab followed by nivolumab alone or ipilimumab plus placebo followed by placebo alone.

The ipilimumab-nivolumab combination produced an overall response rate of 60% in the 109 patients without BRAF mutations, including 17% complete response and 43% partial response rates.

The ipilimumab-placebo combination resulted in overall response rate of 11%, with no complete responses and 11% partial response rate.

Among the 33 patients with BRAF V600 mutations, overall response rate was 44%, including 17% complete response and 26% partial response rates.

FDA approves Opdivo for unresectable or metastatic melanoma
Ipilimumab and nivolumab produced better treatment response in patients with advanced melanoma who had received no prior treatment.
Giving the two immunotherapies ipilimumab and nivolumab simultaneously yielded better treatment responses than ipilimumab alone in patients with advanced melanoma who received no prior treatment.
READ FULL ARTICLE From Medical Express
Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs